Risk factors for the development of bacterial infections in multiple myeloma treated with two different vincristine-adriamycin-dexamethasone schedules.
@article{Cesana2003RiskFF,
title={Risk factors for the development of bacterial infections in multiple myeloma treated with two different vincristine-adriamycin-dexamethasone schedules.},
author={Clara Cesana and Annamaria Nosari and Catherine Klersy and Sara Miqueleiz and Valentina Rossi and Paola Ferrando and Marina Valentini and Luciana Barbarano and Enrica Morra},
journal={Haematologica},
year={2003},
volume={88 9},
pages={
1022-8
},
url={https://api.semanticscholar.org/CorpusID:39988347}
}Patients with profound hypogammaglobulinemia who receive VAD as first line treatment are at a major risk of BI up to the completion of the fourth month of therapy and, if patients require admission, antibacterial prophylaxis with intravenous immunoglobulins could be appropriate and effective.
38 Citations
Reduced risk of bacterial infection in multiple myeloma patients with VAD regimen without intermittent high-dose dexamethasone
- 2011
Medicine
Risk of infection is lower in VAD without HD than in Vad-HD, and the clinical response is equivalent, and VAD-HD should thus be avoided for MM patients with high risk of infection.
Infectious complications in patients with multiple myeloma treated with new drug combinations containing thalidomide
- 2011
Medicine
Patients with MM receiving thalidomide combinations with high tumor burden are at high risk of developing severe infections and require primary antibiotic prophylaxis, whereas in other patients it is questionable, but patient final outcome was not affected by infection development.
Pretreatment Lymphopenia, Poor Performance Status, and Early Courses of Therapy Are Risk Factors for Severe Bacterial Infection in Patients with Multiple Myeloma during Treatment with Bortezomib-based Regimens
- 2016
Medicine
Three pretreatment risk factors associated with SBI in each course of bortezomib treatment in multiple myeloma patients with these risk factors should be more closely monitored for the development of SBI during bortzomib-based treatment.
Lymphocytopenia is associated with an increased risk of severe infections in patients with multiple myeloma treated with bortezomib-based regimens
- 2013
Medicine
It is shown that MM patients who received bortezomib-based regimens are at a higher risk of severe infections within eight cycles of treatment during especially severe lymphocytopenic periods.
Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents.
- 2009
Medicine
Key to the management of infection is the understanding of the specific risk factors and periods during which patients are at risk; this allows the anticipation of the likely pathogen(s) and the application of risk-adjusted prophylactic and treatment strategies.
Infectious complications in multiple myeloma receiving autologous stem cell transplantation in the past 10 years
- 2017
Medicine
Bacteremia was the most common type of microbiologically confirmed infection, and was associated with higher beta-2 microglobulin levels and previous bortezomib treatment, and the main cause of in-hospital mortality in patients who underwent autoSCT.
MBL2 polymorphism and risk of severe infections in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation
- 2006
Medicine
It is indicated that Mannan-binding lectin to some extent protects against the most severe infections during ASCT, and individuals homozygous for wild-type MBL encoding gene (MBL2) have a well-functioning MBL pathway of complement activation.
Effect o f Immunoglobulin Therapy Myeloma Patients Undergoing Autologous Stem Cell Transplantation Treated w ith Immunomodulatory Agents
- 2010
Medicine
Intravenous immunoglobulin (IVIG) has been used successfully to reduce infection rates in phase of MM, with limited data in other stages.
Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy
- 2015
Medicine
We defined the epidemiology and clinical predictors of infection in patients with multiple myeloma (MM) receiving immunomodulatory drugs (IMiDs), proteasome inhibitors (PI) and autologous…
18 References
Outpatient treatment of multiple myeloma with a combination of vincristine, Adriamycin and dexamethasone
- 2001
Medicine
Continuous infusion of VAD over 96 h can be performed on an outpatient basis with a low complication rate, and tumor reduction by more than 25% was found in 85 of the 103 patients.
VAD chemotherapy for refractory multiple myeloma
- 1989
Medicine
As early relapses were seen especially in this group of patients, in the patients with a plasma‐cell LI% of 3 or more, and in patients with previous anthracyclin treatment, early consolidation, with, for instance, high dose melphalan, might improve the prognosis for these patients.
Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first‐line treatment in untreated multiple myeloma
- 1999
Medicine
VAD administered as an outpatient regimen, based on rapid intravenous infusion, is an effective induction regimen for untreated myeloma with a 67% response rate and acceptable toxicity.
INFUSION OF VINCRISTINE AND DOXORUBICIN WITH ORAL DEXAMETHASONE AS FIRST-LINE THERAPY FOR MULTIPLE MYELOMA
- 1989
Medicine
Total therapy with tandem transplants for newly diagnosed multiple myeloma.
- 1999
Medicine
Time-dependent covariate analysis suggested that timely application of a second transplant extended both EFS and OS significantly, independent of cytogenetics and beta-2-microglobulin.
High‐dose dexamethasone for refractory or relapsing multiple myeloma
- 1991
Medicine
In order to assess the efficacy and toxicity of dexamethasone as a single agent without the concomitant infusion of Adriamycin and vincristine (VAD), an ECOG pilot study was initiated using 40 mg by…
Dose-intensive melphalan with stem cell support (CM regimen) is effective and well tolerated in elderly myeloma patients.
- 2000
Medicine
The results indicate that dose-intensity of melphalan can be increased by reinfusing PBPC with acceptable low toxicity, and the combination of CY andMelphalan followed by PBPC is an effective chemotherapy for elderly myeloma patients.